**COMMONWEALTH OF MASSACHUSETTS**

**Board of Registration in Pharmacy**

**NOTICE OF THE REGULARLY SCHEDULED MEETING OF THE** **BOARD OF REGISTRATION IN PHARMACY**

# March 5, 2020

239 Causeway Street ~ Room 417 A&B

Boston, Massachusetts 02114

*If you need reasonable accommodations in order to participate in the meeting, contact the DPH ADA Coordinator Yulanda Kiner, Phone: 617-624-5848 in advance of the meeting. While the Board will do its best to accommodate you, certain accommodations may require distinctive requests or the hiring of outside contractors and may not be available if requested immediately before the meeting.*

**Agenda**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Time** | **#** | **Item** | **Page** | **Contact** |
| **8:30** | **I** | **CALL TO ORDER** |  | K. Tanzer |
|  | **II** | **APPROVAL OF AGENDA** |  |  |
| **8:40** | **III** | **APPROVAL OF BOARD MINUTES**Draft of February 7, 2020 Regular Session Minutes* Introduction of Interns:

o Harpreet Puri- Western New England University |  |  |
| **8:45** | **IV** | **REPORTS*** Applications approved pursuant to Licensure Policy 13-01
* Monthly report from probation
* Board Delegated Review pursuant to Licensure Policy 14-02
* Above Action Levels approved by Staff Action 16-04
* PSUD Report-Policy 17-03
 |  |  |
| **8:50** | **V** | **POLICIES and ADVISORIES*** Policy 2020-03: Pharmacist Graduates of Canadian Pharmacy Schools
* Advisory in Sterile Compound Pharmacies response to HVAC excursion
 |  | W. FrischM. Chan |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **9:00** | **VI** | **APPLICATIONS*** Winchester Pharmacy Pilot Project (DS89848)
* PharmBlue, LLC (DS89961) – Transfer of Ownership
* Radioisotope Life Science (NU10) – Transfer of Ownership
* Walmart Pharmacy 10-2660 (DS2853) – Change of Manager
 |  |  |
| **9:45** | **VII** | **REGULATIONS*** 247 CMR 2.00: Definitions
 |  |  |
| **10:15** | **VIII** | **FLEX*** Election for delegate and alternate to the NABP national conference in May 2020.
 |  |  |
| **10:30** | **IX** | **FILE REVIEW** |  |  |
|  | **1** | SA-INV-15415 | Western MA Compounding, DS89965 |
| **2** | SA-INV-15772 | Baxter Healthcare Corp., DS2892 |
| **3** | SA-INV-15912 | Walgreens #9405, DS3475 |
| **4** | SA-INV-15984 | Metro West Pharmacy, DS90075 |
|  |
| **11:00** | **X** | **M.G.L. c. 112, § 65C SESSION** |  | CLOSED SESSION |
| **11:45** | **XI** | **EXECUTIVE SESSION**The Board will meet in Executive Session as authorized pursuant toM.G.L. c. 30A, § 21(a)(1) for the purpose of discussing the reputation, character, physical condition or mental health, rather than professional competence, of an individual, or to discuss the discipline or dismissal of, or complaints or charges brought against, a public officer, employee, staff member or individual. Specifically, to evaluate the Good Moral Character as required for registration for a pending applicant. |  | CLOSED SESSION |
| **12:00** | **XII** | **LUNCH BREAK** |  |  |
| **1:00** | **XIII** | **M.G.L. c. 112, § 65C SESSION** |  |  |
| **5:00** | **XIV** | **ADJOURNMENT** |  |  |

## COMMONWEALTH OF MASSACHUSETTS BOARD OF REGISTRATION IN PHARMACY

**MINUTES OF THE GENERAL SESSION**

**239 Causeway Street, Fourth Floor ~ Room 417A Boston, Massachusetts, 02114**

**March 5, 2020**

**Board Members Present Board Members Not Present**

Kim Tanzer, PharmD, RPh. President Stephanie Hernandez, Pharm D, BCGP, RPh

Julie Lanza, CPhT, President Elect Patrick Gannon, RPh Leah Giambarresi, Pharm D, RPh, Secretary Susan Cornacchio JD, RN Sebastian Hamilton, Pharm D, RPh

Dr. Richard Lopez, MD Andrew Stein, Pharm D Timothy Fensky, RPh

Carly Jean-Francois, RN, NP (arrives 8:40 AM) Katie Thornell, RPh

Dawn Perry, JD (arrives 9:40 AM)

## Board Staff Present

David Sencabaugh, RPh, Executive Director Monica Botto, Assistant Executive Director Heather Engman, JD, Board Counsel

William Frisch, RPh Director of Pharmacy Compliance Michelle Chan, RPh Quality Assurance Pharmacist Joanne Trifone, RPh, Director of Investigator

Julienne Tran, PharmD RPh, Investigator Gregory Melton, Pharm D, JD, RPh Investigator Christina Mogni, RPh Investigator

Ed Taglieri, MSM, NHA, RPh, PSUD Supervisor Joanna Chow, Office Support Specialist Richard Harris, Program Analyst

**TOPIC I**. Attendance by roll call:

## CALL TO ORDER 8:30 AM

A quorum of the Board was present, established by roll call. President K. Tanzer chaired the meeting and asked if anyone was recording hearing, no one responded. She explained that the Board of Pharmacy was recording the meeting.

Roll call attendance: K. Tanzer, yes; J. Lanza, yes; L. Giambarresi, yes; T. Fensky, yes;

1. Hamilton, yes; R. Lopez, yes; K. Thornell, yes; A. Stein, yes. C. Jean-Francois joins meeting at 8:40 AM and D. Perry joins meeting at 9:40 AM.

|  |  |  |
| --- | --- | --- |
| **Topic II**. | **Approval of Agenda** | **TIME 8:33 AM** |
| **Agenda March 5, 2020** |  |  |
| **DISCUSSION:**Change to Agenda: No changes |  |  |

## ACTION:

Motion by S. Hamilton, seconded by A. Stein and voted unanimously by those present to approve the

agenda with noted change.

Dave asks for the Pharmacy Interns to stand and introduce themselves and also introduces the Western New England Pharmacy APPE student: Harpreet Puri

|  |  |  |
| --- | --- | --- |
| **Topic III** | **Approval of Board Minutes** | **TIME: 8:36 AM** |
| **Minutes****1. Draft, 2/6/20 Session Minutes** |  |  |
| No noted Changes. |  |  |

## Action:

Motion by S. Hamilton, seconded A. Stein, and voted unanimously to approve the regular session minutes of 2/6/20 with noted changes.

## TOPIC IV Reports

**Applications approved pursuant to Licensure Policy 13-01 Time: 8:36 AM**

**Discussion**: M. BOTTO reported there were thirty-seven (37) Change of Manager applications, four (4) Renovation applications, and two (2) New Community Pharmacies applications approved pursuant to Licensure Policy 13-01.

So noted

## TOPIC IV REPORTS

**Monthly Report from Probation Time: 8:37 AM**

**Discussion**: M. BOTTO noted that zero (0) report(s) from probation have been reported since last Board meeting.

So noted

## TOPIC IV REPORTS

**Monthly Report from BDR pursuant to Policy 14-02 Time: 8:37 AM**

**Discussion**: M. BOTTO noted that there was eight (8) Board Delegated Review case heard on March 2, 2020. There were seven (7) CE self-disclosures (SA-INV-16024, SA-INV-16025, SA-INV-16026, SA-INV- 16027, SA-INV-16030, SA-INV-16031, SA-INV-16036) which were closed with discipline not warranted and remediation complete and one (1) CE self-disclosure (SA-INV-16038) which was closed, no violation. The Board Delegated Review session was attended by Kim Tanzer as the Board President, W. FRISCH Director of Pharmacy Compliance, H. ENGMAN as Board Counsel, and Executive Director D. SENCABAUGH.

So noted

## TOPIC IV REPORTS

**Above Action Levels Approved by Staff Action 16-04 Time: 8:37 AM**

**Discussion**: M. BOTTO noted that zero (0) above action level report has been reported since last Board meeting pursuant to Licensure Policy 16-04.

So noted

## TOPIC IV REPORTS

**PSUD Report by Staff Action 17-03 Time: 8:38 AM**

**Discussion**: E. TAGLIERI noted that in February 2020, there was one (1) inquiry, one (1) successful completion and thirteen (13) active participants.

So noted

## TOPIC V Policies and Advisories

* 1. **Policy 2020-03: Pharmacist Graduates of Canadian Pharmacy Schools Time: 8:38 AM Presented by:** M. CHAN

**Recusal:** None

**Discussion:** This new policy updates and replaces Policy 2000-02 on Canadian Colleges/Universities of Pharmacy Education Licensing for Canadian Graduates.

Between 1993 and 2004, ACPE considered Canadian pharmacy school curriculum to be equivalent to that of the schools in the United States. For pharmacists who wish to reciprocate their license to Massachusetts and have been Canadian educated during this time-frame with a license to practice are only required to complete a 300 hour internship in addition to NAPLEX and MPJE. The requirement for the Test of Spoken English has been removed.

Outside of this time period, the usual foreign pharmacist process would apply requiring a 1500 hour internship, the Foreign Pharmacy Graduate Equivalency Examination (FPGEE), as well as NAPLEX and MPJE.

**Action:** Motion by T. FENSKY, seconded by J. LANZA, and voted unanimously by those present to approve Policy 2020-03: Pharmacist Graduates of Canadian Pharmacy Schools.

## Advisory on Sterile Compounding Pharmacy Response to HVAC Excursions Time: 8:40 AM Presented by: W. FRISCH

**Recusal:** None

**Discussion:** This new advisory recommends response and remediation steps in the event of an excursion in temperature, humidity, or differential pressure resulting from HVAC system malfunction or an interruption of HVAC system operation.

This advisory was a topic of discussion at the October 30, 2019 meeting of the Advisory Committee to the Board because a need had been identified through licensee inquiries on how to handle these excursions.

The Advisory Committee feedback centered on creating general guidance for facilities to prepare for and respond to excursions based on facility-specific excursion limits. The advisory includes general recommendations and a general response plan for all excursions. There is also guidance on compounding during remediation after action levels have been exceeded.

**Action:** Motion by T. FENSKY, seconded by J. LANZA, and voted unanimously by those present to approve Advisory on Sterile Compounding Pharmacy Response to HVAC Excursions.

## TOPIC VI Applications

1. **Winchester Pharmacy Pilot Project DS89848 Waiver Request TIME: 8:42 AM**

REPRESENTED BY**:** Steve MacNeil (Owner of Winchester Pharmacy,) Bill McGuire (Omnicell)

RECUSAL: M. BOTTO

DISCUSSION: Winchester Pharmacy is requesting a waiver for 247 CMR 8.04 (4)(e) as well as a limited waiver for final pharmacist verification using the VBM pharmacy automation repackages vision system. Phase II Pilot Results from VBM data collection showed when cards and pills are checked by the machine, approved cards were 100% accurate. Refer to handout on Winchester Pharmacy- Phase II Pilot Results VBM data collection. Based on the pill images, the robot is able to flag incorrect cards, which requires a pharmacist check. The system can fit up-to 14 pills into a bubble. Half tablets can also be used with the system; however, the technician/pharmacist will have to put in half tablets into the machine themselves for it to be packaged.

* 1. STEIN recommends the pharmacist to check the cards three times (morning, afternoon, and evening) daily instead of 5% of the cards. K. TANZER agrees to A. STEIN’s recommendation since pharmacists are already checking cards that are rejected or flagged by the machine. Winchester Pharmacy representatives accepted the recommendation.

The Board mentioned that a waiver is approved for 5 years, however, once CMR 9 is promulgated, a new waiver would be required.

ACTION: Motion by L. GIAMBARRESI, seconded by T. FESNKY, voted unanimously by those present to approve the application for a petition for a waiver of the provisions of 247 CMR initial and renewal requests.

## Pharmblue, LLC DS89961 Transfer of Ownership TIME: 9:12 AM

REPRESENTED BY**:** Megan C. Masse (MOR)

RECUSAL: None

DISCUSSION: PharmBlue is being acquired by NS & Associates, a California limited liability company. There is only one (1) PharmBlue pharmacy in Massachusetts, which is located in Attleboro. M. MASSE is the only practicing pharmacy manager at this location. Regular day-to-day functions will remain the same. The pharmacy’s bulk of business is from 340B contract in Massachusetts and Connecticut. The pharmacy is a retail pharmacy which has been open for almost 5 years. They work primarily with in- service organizations and provide multi-dose packaging. The pharmacy also conducts compliance packaging. If the pharmacy gets a compounding prescription, they provide it to a partner pharmacy located in Pennsylvania and do not conduct it at their site.

ACTION: Motion by T. FENSKY, seconded by S. HAMILTON, voted unanimously by those present to approve the application for transfer of ownership with waiver of the provisions of 247 CMR initial and renewal requests.

## Radioisotope Life Sciences NU10 Transfer of Ownership TIME: 9:16 AM

REPRESENTED BY**:** Anne Siewko (MOR)

RECUSAL: None

DISCUSSION: GE Healthcare is being acquired by RLS (Radioisotope Life Sciences). A. STEIN noted that any pharmacy decision at RLS will be addressed by pharmacist A. SIEWKO. A. SIEWKO acknowledged A. STEIN and noted that she has been with the company for 24 years. L. GIAMBARRESI asked whether the pharmacy only dispenses schedule VI drugs. A. SIEWKO confirmed that the pharmacy dispenses only schedule VI drugs and nothing else.

ACTION: Motion by S. HAMILTON, seconded by T. FENSKY, voted unanimously by those present to approve the application for transfer of ownership.

## Walmart Pharmacy 10-2660 DS2853 Change of Manager TIME: 9:19 AM

REPRESENTED BY**:** Nicole Caiazzo (MOR)

RECUSAL: None

DISCUSSION: Nicole Caiazzo presents before the Board to request approval for a change in manager at Walmart Pharmacy. N. CAIAZZO states she went on maternity leave after working for 1 year. N. CAIAZZO also stated that it was her partner who had taken over before and she is aware of all the functions in the pharmacy, along with any issues that may be present. President K. TANZER asked whether if any issues were concerning. N. CAIAZZO responded that there are no concerning issues and will be careful with staff ratios and PMP.

ACTION: Motion by L. GIAMBARRESI, seconded by J. LANZA, voted unanimously by those present to approve the application for change of manager of record.

## TOPIC VII Flex

Dave discussed the NABP National Conference in May of 2020. The board discussed and voted to approve the following voting delegate and alternate:

1. Delegate: Leah Giambarresi
2. Alternate Delegate: Sebastian Hamilton

Also discussed was for the Board to watch for communication on Treasure Nominations as well as resolutions to consider for the May 2020 National Conference. The Board will consider resolutions to present from Massachusetts at a meeting prior to 5/2020.

## Action:

Motion by J. Lanza, seconded K. Tanzer, and voted unanimously to approve the voting delegate and alternate delegate for the 2020 NABP National Conference.

## TOPIC VIII Regulations

**1. 247 CMR 2.0 Definitions Time: 9:35 AM**

**Presented by:** M. CHAN and W. FRISCH

**Recusal:** None

**Discussion:** Information was presented regarding the proposed additions and amendments to 247 CMR

2.00 “Definitions and Severability”. Before many of the new regulations had been drafted, a public hearing was held for this section in 2016 and changes had been made based on the comments. Now that the new regulations have all been drafted, several new necessary definitions were identified and have thus been added. Given the significant changes, M. CHAN and W. FRISCH are seeking approval for an administrative review and a second public hearing.

**Action:** Motion by A. STEIN, seconded by T. FENSKY, and voted unanimously by those present to approve the changes to 247 CMR 2.00 “Definitions and Severability” and send for an administrative review in anticipation of a second public hearing.

|  |  |  |
| --- | --- | --- |
| **TOPIC IX** | **File Review** |  |
| Case #1SA-INV-15415 | Western MA Compounding Center, DS89965 | Time: 9:47 AM |
| RECUSAL: NONE |  |  |

DISCUSSION: C. Mogni presented and summarized the investigative report that pertained to these matters.

* Probation effective 06/26/2019 – 06/26/2020 for compounding preparations that are essentially copies of a commercially available drug products.
* On 7/29/19, WMCC provided a list of 666 compounds prepared from 6/26/19 to 7/26/19 to the BORP in accordance with the terms of the Consent Agreement for Probation. A review of the list of compounded preparations identified compounds that were potentially copies of commercially available products. BORP staff recommended OPP Pharmacy Investigators perform a Site Visit (ISP- 12883) which occurred on 8/13/19.
* On 8//22/19, WMCC was notified of the staff assignment with a request for compounding logs with corresponding prescriptions for 50 preparations that were potential copies of commercially available products and any relevant documentation obtained from providers.
* In a response received 9/16/19, MOR Sprecher stated the “FDCA does not outright ban compounding of drug products that are essentially copies of commercially available drug products, only that such compounding shall not occur routinely, in ‘regular or inordinate amounts’”. Additionally, “the FDA unequivocally states that the whole of section 503(A), itself, does not apply to drugs compounded for animals”. Of note, the requirements of USP 795 applies to humans and animals and MGL 112 39D(a)(1) defines the parameters of compounding related to commercially available products. MOR Sprecher contended that veterinary drugs are not available to retail pharmacies; therefore, if he received a prescription for an animal, it would be reasonable to assume the intention of the veterinarian was the medication was to be compounded.
* 14 of 17 compounds for veterinary preparations and 12 of 23 compounds for human preparations (26 total of 50) were identified as potential copies of commercially available drug products; all veterinary compounds used API which is not permitted per 21 CFR 530.13.
* A formal evaluation process was implemented to avoid routinely compounding drugs that are essentially copies of commercially available drugs. The new SOP states, “The pharmacist must make a reasonable effort to determine the commercial availability of a drug product before he or she

compounds a replacement preparation and also determine whether the compounded drug is essentially a copy of a commercially available drug. According to FDA guidance, section 503A does not apply to prescriptions for animal patients”.

* The matter was heard at the 12/5/19 Board meeting at which time more information was requested. A letter of communication was sent to WMCC regarding the definition of compounding in MGL 112

§39D which includes veterinary compounding.

* Compounding logs and requested prescriptions from 7/27/19 to 9/26/19 were provided that identified 8 additional compounded preparations that were potential copies of commercially available products. Additionally, WMCC was identifying 2 OTC products as being compounded when they were only dispensed from a commercially available product. The quarterly list submitted per their probation identified 11 additional drugs in various forms and dosages that were potential copies of commercially available products.
* CA: In the response received on 12/23/2019, MOR Sprecher acknowledged receipt of the reminder letter. MOR Sprecher provided a revised WMCC SOP No. 1.063 “Determining the Commercial Availability of FDA-Approved Drug Products and Whether a Compounded Drug Product is Essentially a Copy Thereof” which expanded the “analysis of whether a prescription is written for an (sic) FDA- approved drug to include veterinary prescriptions”.

ACTION: Motion by A. STEIN, seconded by T. FENSKY, and voted unanimously by those present, to CLOSE the matter (SA-INV-15415), with notice of violation of probation and include a copy of Policy 2020-02: Compounding of Commercially Available Drugs**.**

Case #2

SA-INV-15772 Baxter Healthcare Corp., DS2892 Time: 10:01 AM RECUSAL: NONE

DISCUSSION: C. MOGNI presented and summarized the investigative report that pertained to these

matters.

* During a compliance inspection (ISP-13382) on 10/30/2019, it was noted that the data entry of prescriptions was performed in Illinois. The Pharmacy is a closed-door facility with a limited scope of only supplying prescription peritoneal dialysis solutions along with the devices needed for dialysis in patients’ homes. The large, heavy packages of dialysis solution can only be moved by a forklift. Because of the size and weight of items, unlicensed personnel assembled the dialysis solutions for dispensing.
* On 12/07/2017, SA-INV-11015 was heard at the Board meeting concerning a compliance inspection (ISP-6632) conducted on 01/12/2017 at the Pharmacy for the same issue. The investigation confirmed data entry and PV1 with DUR occurred in Deerfield, Illinois. The Board voted to close the staff assignment, no discipline warranted, with a reminder in the closure letter that data entry cannot be done from out-of-state. The closure letter (dated 12/07/2017) sent to the Pharmacy stated, “As a reminder, data entry cannot be completed off site”.
* In his response MOR Yang misinterpreted the MA requirement and indicated there currently is not a MA licensed pharmacist in Deerfield, IL “as one is not required, according to BORP Policy 2019-01 (item V (b)), which states: *Prescriptions may be processed outside the premises of a licensed Massachusetts pharmacy provided that the processes are verified by a Massachusetts licensed pharmacist or performed in a pharmacy licensed by the Board.* These processes are verified by the

Massachusetts-licensed pharmacists on staff at the Bedford pharmacy, therefore fulfilling the requirement”.

* CA: On 01/09/2020, Pharmacist Nona DeCastro submitted an application to NABP for reciprocity of her pharmacist license from IL to MA. On 01/28/2020, a copy of the notarized “Pharmacist Reciprocal Licensure Application” for Nona DeCastro submitted to Professional Credential Services, Inc. was provided.

ACTION: Motion by S. HAMILTON, seconded by K. TANZER, and voted unanimously by those present, to CLOSE the matter (SA-INV-15772), No Discipline Warranted, Remediation Complete pending confirmation of MA licensed pharmacist in place.

Case #3

SA-INV-15912 Walgreens #9405, DS3475 Time: 10:09 AM RECUSAL: NONE

DISCUSSION: C. MOGNI presented and summarized the investigative report that pertained to these matters.

ACTION: Moved to Closed Session (65C) Case #4

SA-INV-15984 Metro West Pharmacy, DS90075 Time: 10:19 AM

RECUSAL: NONE

DISCUSSION: C. MOGNI presented and summarized the investigative report that pertained to these matters.

* BORP staff were notified on 12/19/2019 that a flyer with the Pharmacy’s header was either being attached to the patient’s prescription or being handed to the patient directing them to the Pharmacy. A redacted statement indicated, “Your prescription will be sent to MetroWest Pharmacy. Thank you for choosing MetroWest Pharmacy” and listed the services of the Pharmacy with an area for “Provider Notes”.
* MOR Patel acknowledged the wording on the Pharmacy information sheet could have been misinterpreted affecting the patient’s freedom to choose a pharmacy. MOR Patel asserted the goal was to show patients the services the Pharmacy offers with no intension to limit pharmacy choice.
* MOR Patel submitted copies of 5 flyers provided to 33 prescribers in 19 locations. In addition to the flyer at issue, flyers advertising an overview of patient services aimed at patients; an overview of services aimed at prescribers; “Ophthalmology Management”; and multi-dose packaging were submitted. The Pharmacy promoted itself as a “specialty pharmacy” which MOR Patel clarified as a reference to specialty medications that can be filled at a retail setting.
* CA: The flyer was updated to include the removal of “Your prescriptions have been sent to MetroWest Pharmacy” and the addition of a disclaimer indicating You have the option to fill your prescriptions at any pharmacy of your choice” and the Pharmacy has no affiliations with any prescribers, wholesalers, or manufacturers. Updated copies of the flyers for the overview of patient services aimed at

prescribers and “Ophthalmology Management” were also provided with the “specialty” references removed and disclaimers added.

ACTION: Motion by S. HAMILTON, seconded by J. LANZA, and voted unanimously by those present, to CLOSE the matter (SA-INV-15984), No Violation.

## Topic XI: EXECUTIVE SESSION Time: 10:24 AM

**Read by K. Tanzer**

DISCUSSION:

ACTION: At 10:24 AM President K. Tanzer reads the statement on reasons for Executive Session.

## Topic XI: Executive Session Call to Order: Time: 12:11 PM

By: K. Tanzer

ACTION: Motion by L. Giambarresi seconded by J. Lanza, and voted unanimously by roll call to call the 3/5/20 meeting of the Executive Session to order.

Roll call attendance: K. Tanzer, yes; J. Lanza, yes; L. Giambarresi, yes; T. Fensky, yes;

1. Hamilton, yes; R. Lopez, yes; K. Thornell, yes; A. Stein, yes. C. Jean-Francois, yes; D. Perry, yes.

## Topic X: M.G.L. 65 C #1 Time: 10:34 AM

DISCUSSION: None

ACTION: President K. Tanzer request a motion to enter M.G.L 65 c Session.

At 10:34 AM A. Stein, seconded by J. Lanza and voted unanimously by all those present to enter M.G.L. chapter 65 c Session:

## Topic XIV: ADJOURMENT OF MEETING TIME: 3:18 PM

ACTION: Motion by S. Hamilton seconded by J. Lanza, and voted unanimously by those present, to adjourn from General Session.

EXHIBITS USED DURING THE OPEN SESSION OF THE MEETING

* 1. Draft Agenda of the 3/5/20 General Session
	2. Draft Minutes of the 3/5/20 Meeting
	3. Report on Applications approved pursuant to Licensure Policy 13-01
	4. Report on probation
	5. Report on Board Delegated Complaint Review to licensure policy 14-02
	6. Report on Above Action Levels approved by Staff Action 16-04
	7. Report on PSUD 17-03
	8. Staff Action Policy 13-01 (Revision): Licensure Applications and Notices
	9. Policy 2020-03: Pharmacist Graduates of Canadian Pharmacy Schools
	10. Advisory in Sterile Compound Pharmacies response to HVAC excursion
	11. Applications: Winchester Pharmacy Pilot Project DS89848
	12. Applications: PharmBlue, LLC DS89961 Transfer of Ownership
	13. Applications: Radioisotope Life Science (NU10) Transfer of Ownership
	14. Applications: Walmart Pharmacy 10-2660 DS2853 Change of Manager
	15. 247 CMR 2.00 Definitions
	16. SA-INV-15415 Western MA Compounding DS89965
	17. SA-INV-15772 Baxter Healthcare Corp; DS2892
	18. SA-INV-15912 Walgreens #9405 DS3475
	19. SA-INV-15984 Metro West Pharmacy DS90075

Respectfully Submitted,

Leah Giambarresi, PharmD, RPh, Secretary